RT @PokrajacAna: Big topic for public health to chew on. Similar to access 2medication for #T2D in the Uk according to #CPRD https://t.co/r…
Big topic for public health to chew on. Similar to access 2medication for #T2D in the Uk according to #CPRD https://t.co/rYclRIZpai @Roxytonin @DamianFog
We published paper on this - actually all hard work done by @sama_wilkinson @Roxytonin and @LSHTM @DamianFog and I merely gave a hand 😎 Here it is: https://t.co/DGRoBNLqV8
RT @PokrajacAna: pleased 2see partnership 4good cause: @ADA_DiabetesPro & Baxter. We published on factors influencing the choice of 💊for #T…
RT @PokrajacAna: pleased 2see partnership 4good cause: @ADA_DiabetesPro & Baxter. We published on factors influencing the choice of 💊for #T…
pleased 2see partnership 4good cause: @ADA_DiabetesPro & Baxter. We published on factors influencing the choice of 💊for #T2DM in the UK https://t.co/DGRoBNtQ3A @sama_wilkinson @Roxytonin @DamianFog @DanielJDrucker @kamleshkhunti @Azeem_Majeed @ClareHam
@parthaskar @kamleshkhunti @drkevinfernando @DSNforumUK @drmohanv @ShivaniM_KC @Shahed__Ahmad So SGLT2i & DPP4i may be more effective in people of Asian dissent. Ironic that at least in the U.K. they are less likely to be prescribed in that group (@Rox
@RichardHaynes3 @drpatrickholmes @CPRD @kamleshkhunti @AmarPut @DSNforumUK @AbdTahrani @HPILLminster @sama_wilkinson Sorry that was a rubbish link. Bah to new pubmed https://t.co/o8zuiGDuB1
Further evidence on disparity of care and access to newer therapies for #T2DM in the UK. Findings support those in paper by @sama_wilkinson @Roxytonin @DamianFog https://t.co/DGRoBNtQ3A
@AbdTahrani Here you go! A reminder https://t.co/DGRoBNtQ3A
RT @PokrajacAna: @hormone_doc @bernardkhoo @LSHTM @Roxytonin Here is an example https://t.co/DGRoBNtQ3A looking 4a help raising awareness &…
RT @PokrajacAna: @hormone_doc @bernardkhoo @LSHTM @Roxytonin Here is an example https://t.co/DGRoBNtQ3A looking 4a help raising awareness &…
@hormone_doc @bernardkhoo @LSHTM @Roxytonin Here is an example https://t.co/DGRoBNtQ3A looking 4a help raising awareness & addressing the issue; socio-economic status matters more than either #kidney function or #CVrisk when it comes to choice of #diab
Complex but pristine stats. Hope findings accessible 2wider audience. Poorer and older UR less likely UR 2get a drug with #cardiovascular evidence & without #hypoglycaemia. We must change that! @davidpilling @RoyLilley @OlaRosling @Gapminder @Roxytonin
Factors associated with choice of intensification treatment for type 2 | CLEP @DovePress https://t.co/DGRoBNtQ3A @ABCDiab
@bengoldacre Here you go: https://t.co/DGRoBNtQ3A
RT @PokrajacAna: Yeah...see our paper. More to come from the same kitchen at @ehr_lshtm @Roxytonin @sama_wilkinson https://t.co/DGRoBNtQ3A…
Yeah...see our paper. More to come from the same kitchen at @ehr_lshtm @Roxytonin @sama_wilkinson https://t.co/DGRoBNtQ3A
@profmjdavies @brendonneuen @parthaskar @HelenRSalisbury @DamianFog @drpaddymark @kamleshkhunti @AmDiabetesAssn @Roxytonin . @profmjdavies I wish that was the state of affairs. Data says differently: https://t.co/DGRoBNtQ3A
Here is the link https://t.co/DGRoBNtQ3A
RT @Roxytonin: @DrAndrewBaldwin @parthaskar @ABCDiab That's right, and low SES (independently), and older people. Paper here - https://t.co…
RT @ABCDiab: Laurie Tomlinson on Twitter https://t.co/IoKK68FcSc https://t.co/dsFEGUwQIy
Laurie Tomlinson on Twitter https://t.co/IoKK68FcSc
@DrAndrewBaldwin @parthaskar @ABCDiab That's right, and low SES (independently), and older people. Paper here - https://t.co/ey9TWIp4JA https://t.co/eQXU7KGuAk
https://t.co/qfYSmN3bYI @Roxytonin (need @ for Sam!) @DamianFog
Factors associated with choice of intensification treatment for type 2 diabetes after metformin monotherapy: a cohort study in UK primary care. https://t.co/HVrR0ac1JX
RT @Roxytonin: Our work comparing effects of oral drugs for type II DM continues: new paper shows how different the characteristics of pts…
Another great pharmaco-epi paper & summary thread from @sama_wilkinson & @Roxytonin on the new glucose lowering agents and patterns of use in the UK
RT @Roxytonin: Our work comparing effects of oral drugs for type II DM continues: new paper shows how different the characteristics of pts…
This is hugely interesting, We will explore if we have similar findings in @HealthierNWL
RT @Roxytonin: Our work comparing effects of oral drugs for type II DM continues: new paper shows how different the characteristics of pts…
RT @Roxytonin: Our work comparing effects of oral drugs for type II DM continues: new paper shows how different the characteristics of pts…
RT @Roxytonin: Our work comparing effects of oral drugs for type II DM continues: new paper shows how different the characteristics of pts…
RT @Roxytonin: Our work comparing effects of oral drugs for type II DM continues: new paper shows how different the characteristics of pts…
RT @Roxytonin: Our work comparing effects of oral drugs for type II DM continues: new paper shows how different the characteristics of pts…
RT @Roxytonin: Our work comparing effects of oral drugs for type II DM continues: new paper shows how different the characteristics of pts…
Interesting work @Roxytonin. Do you think that this is reflective of wider prescribing habits for new drugs and healthcare technologies? I suspect that it is - but it’s a worrying finding.
RT @PokrajacAna: What defines your choice for 2nd oral agent in #T2DM: evidence or...? Food for thought @parthaskar @thedoctorkhan @Azeem_M…
RT @PokrajacAna: What defines your choice for 2nd oral agent in #T2DM: evidence or...? Food for thought @parthaskar @thedoctorkhan @Azeem_M…
RT @PokrajacAna: What defines your choice for 2nd oral agent in #T2DM: evidence or...? Food for thought @parthaskar @thedoctorkhan @Azeem_M…
RT @PokrajacAna: What defines your choice for 2nd oral agent in #T2DM: evidence or...? Food for thought @parthaskar @thedoctorkhan @Azeem_M…
What defines your choice for 2nd oral agent in #T2DM: evidence or...? Food for thought @parthaskar @thedoctorkhan @Azeem_Majeed @AbdTahrani @ABCDiab @DiabetesUK
Our work comparing effects of oral drugs for type II DM continues: new paper shows how different the characteristics of pts prescribed SGLT2is and DPP4is are compared to SUs making cohort studies of outcomes difficult: https://t.co/wuRCWMkaaD https://t.co/